US 11,655,240 B1
Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
Weiye Wei, Beijing (CN); Jiannan Yang, Beijing (CN); Xiaotao Wu, Beijing (CN); Taotao Zhao, Beijing (CN); Hao Wang, Beijing (CN); Chao Li, Beijing (CN); Lei Qu, Beijing (CN); and Bin Wang, Beijing (CN)
Assigned to BEIJING GRAND JOHAMU PHARMACEUTICAL COMPANY, LTD., Beijing (CN); and NANJING GRITPHARMACO., LTD., Nanjing (CN)
Filed by BEIJING GRAND JOHAMU PHARMACEUTICAL COMPANY, LTD., Beijing (CN); and NANJING GRITPHARMACO., LTD., NanJing (CN)
Filed on Oct. 12, 2022, as Appl. No. 17/964,389.
Claims priority of application No. 202210500296.8 (CN), filed on May 10, 2022; application No. 202210644417.6 (CN), filed on Jun. 9, 2022; and application No. 202211119888.1 (CN), filed on Sep. 15, 2022.
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/14 (2006.01); A61P 31/14 (2006.01); A61K 9/20 (2006.01)
CPC C07D 403/14 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystal form comprising a compound of Formula (I) and fumaric acid:

OG Complex Work Unit Chemistry
wherein,
an X-ray powder diffraction pattern of the crystal form obtained by using Cu-Kα radiation comprises at least three peaks selected from the group consisting of 10.94°±0.2° 2θ, 19.06°±0.2° 2θ, 23.50°±0.2° 2θ, and 24.66°±0.2° 2θ.